Good news! Soon we will all be skinny like skeletons at this rate of progress! Just kidding!
"Eli Lilly has announced the results of a clinical trial of a GLP-1 agonist weight loss pill. The drug, called orforglipron, functions similarly to semaglutide (Ozempic) but does not need to be injected or refrigerated. And, thanks to its molecular structure, orforglipron should also be much cheaper and easier to produce."
"... The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint ...
About orforglipron
Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.
Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published the preclinical pharmacology data of this molecule together. Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. ..."
Eli Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial (original news release)
Notice even taking a placebo can reduce your weight substantially
No comments:
Post a Comment